New research from Finland and the UK just turned cardiology on its head. Researchers found bacterial DNA inside coronary plaques. Not contamination. Real bacteria living in your arteries.

This changes everything we thought we knew about heart attacks.

The problem with current imaging. Your cardiologist looks at your arteries with IVUS or OCT. They see plaque. They measure how thick it is. They spot lipid pools. They tell you if a vessel is narrowed.

But they miss the most important part. They can't see inflammation. They can't tell if bacteria are hiding in those plaques, waiting to trigger the next heart attack.

Think about it. Twenty percent of heart attack victims have perfect cholesterol. Normal blood pressure. They exercise. They eat right. Then one day, they're in the ER. Current imaging failed them. It showed structure but missed biology.

What VerAvanti's Scanning Fiber Endoscope (SFE) will show you

Scanning Fiber Endoscopy works differently. It will detect functional changes in living tissue. When you shine light on inflamed tissue, it glows differently than healthy tissue. That's autofluorescence.

SFE will show your cardiologist which plaques are metabolically active. Which ones are inflamed. Which ones are about to rupture.

If oral bacteria are driving that inflammation, and research says they are, then SFE will be the first tool that lets doctors see it happening in real time.

No more guessing. No more wondering why someone with great numbers just had a heart attack.

Why This Matters Now

Here's what researchers discovered. Oral bacteria travel through your bloodstream. They sneak into plaques through tiny new blood vessels. They set up camp. They form biofilms and go dormant.

For years, nothing happens. You feel fine. Your tests look good. Then the bacteria wake up. They trigger inflammation. The plaque destabilizes. It ruptures. You have a heart attack.

Half of cardiovascular disease patients have few traditional risk factors. Genetics explain only 10 to 15 percent of cases. Something else is driving the disease. That something is infection.

The Antibiotic Story Doctors tried antibiotics for heart disease years ago. The trials failed. Everyone assumed the infection theory was wrong.

Turns out the timing was wrong. Bacteria are vulnerable right after a heart attack when the plaque ruptures. Within days, your immune system engulfs them. What's left is a biofilm that laughs at antibiotics.

Those old trials started treatment months after cardiac events. Way too late.

A Finnish research team gets it now. They're starting a new trial next year. Three days of antibiotics immediately after diagnosis. Hit the bacteria while they're exposed.

Where SFE Comes In

But here's the real question. Why wait for a heart attack?

SFE will identify inflammatory plaques before they rupture. Before you have symptoms. Before you end up in the ER.

Your cardiologist will see inflammation during a routine catheterization. They'll know you need intervention. Maybe that's antibiotics. Maybe it's more aggressive treatment. Either way, they'll have real data instead of risk scores.

And here's the beautiful part. SFE will let them check if treatment worked. Image before antibiotics. Image a few weeks later. See if the inflammation went down.

For the first time, cardiologists will treat based on what's actually happening in your arteries, not statistical probability.

How it Will Work

SFE will fit into procedures doctors already do. Millions of catheterizations happen every year. The SFE probe is smaller than current imaging catheters. No extra arterial access needed. No contrast dye required.

Your doctor threads the catheter in. Takes images. Gets functional data about inflammation and metabolic activity. Makes treatment decisions based on what they see.

The workflow doesn't change. The information quality does.

What Patients Will Get

You walk into your cardiologist's office. Your cholesterol is fine. Your blood pressure is good. But you're worried because your dad had a heart attack at 50.

With current imaging, your doctor looks at plaque burden. They put you on a statin. They tell you to exercise. They're managing risk factors.

With SFE, your doctor will see if inflammation is active in your plaques. If it is, you get aggressive treatment. If it's not, you avoid unnecessary procedures and medications.

Personalized medicine based on your actual biology. Not population averages.

The Research Angle

The bacteria-heart disease connection needs more work. Researchers need to answer basic questions.

Which plaques actually contain bacteria? Does bacterial load correlate with inflammation intensity? Do antibiotics reduce inflammation? Which patients benefit most?

SFE will give them the tool to study this. They'll identify inflammatory plaques during catheterization. They'll biopsy those exact spots. They'll correlate imaging with bacterial DNA tests and immune markers.

Right now, they're working blind. SFE will turn the lights on.

What Makes SFE Different

IVUS gives you anatomy. How big is the plaque? How much does it narrow the vessel?

OCT gives you microstructure. What's the plaque made of? How thick is the fibrous cap?

Both are structural. Static. They show you what's there.

SFE will show you what's happening. Active or dormant. Inflamed or stable. High risk or low risk.

If bacteria drive inflammation and inflammation drives rupture, you need to see the inflammation.

Everything else is just describing the crime scene after the fact.

The bigger picture

The paradigm is shifting right now. Heart disease isn't just cholesterol accumulation anymore. Infection plays a role.

Researchers found that middle-aged sudden cardiac death victims had more dental infections than people who died from other causes. The same bacteria that cause gum disease show up in coronary plaques.

Your dentist might become part of your cardiac care team. Treating dental infections might prevent heart attacks.

But you need to know if you have the problem first. You need imaging that reveals infection-driven inflammation.

Where we go from here

The Finnish trial starts next year. Other research groups will jump in. The data will pile up. Treatment protocols will change.

Cardiologists will need tools to identify which patients benefit from antimicrobial therapy. They'll need to monitor treatment response. They'll need to predict which plaques will rupture.

SFE will answer all three questions. The technology is approaching FDA submission. The clinical application is obvious. The timing couldn't be better.

You can't manage what you can't measure. Structure alone doesn't predict who has a heart attack. Biology does.

SFE will show you the biology.

Source: Allerton, J. (2025, December 11). Are Heart Attacks Infections? Interview with Pekka J. Karhunen on bacterial DNA in coronary plaques and implications for myocardial infarction prevention. Research conducted by teams in Finland and the UK examining the role of oral bacteria in atherosclerotic plaque inflammation and coronary artery disease progression.